Stock 4507 SHIONOGI & CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-20 am EDT 		5-day change 1st Jan Change
7,144 JPY +0.21% Intraday chart for Shionogi & Co., Ltd. -4.61% +5.09%
May. 14 Japan's Nikkei drifts sideways as more earnings, US CPI awaited RE
May. 13 Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Japan's Nikkei drifts sideways as more earnings, US CPI awaited
RE
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
AQ
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial
RE
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund
AQ
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd
CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
CI
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents
AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares
AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections
AQ
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares
MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)
CI
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome
AQ
Shionogi Completes Up to 75 Billion Yen Share Buyback
MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.
CI
Final dividend
FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.
CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.
CI
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year
AQ
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial
MT
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW